Deep Track Capital reports 9.99% ProMIS Neurosciences (PMN) ownership cap

Rhea-AI Filing Summary

ProMIS Neurosciences Inc. received a Schedule 13G filing showing that Deep Track Capital and related entities beneficially own 902,561 common shares, representing 9.99% of the company’s common stock as of February 6, 2026.

The filing explains that this percentage is calculated using 9,034,646 common shares, combining 2,152,444 shares outstanding as of November 12, 2025, 6,815,296 shares issued on January 30, 2026, and 66,906 shares that could be converted up to a 9.99% maximum ownership cap.

The beneficial ownership includes 835,655 warrants that are exercisable into common shares but are subject to a 9.99% “Maximum Percentage” limitation, so exercises cannot push Deep Track’s collective holdings above that threshold.

Insights

Equity ownership & governance analyst

Deep Track Capital discloses a capped 9.99% stake in ProMIS.

The Schedule 13G shows Deep Track Capital and affiliates holding 902,561 ProMIS common shares, or 9.99% of the class, as of February 6, 2026. This includes positions held through Deep Track Biotechnology Master Fund and Deep Track Special Opportunities Fund.

Ownership is calculated over 9,034,646 shares, combining shares outstanding from a November 12, 2025 10-Q, additional shares issued in an January 30, 2026 8-K, and 66,906 shares potentially convertible within a 9.99% cap. The filing states the securities are not held to change or influence control.

A key structural feature is 835,655 warrants that are exercisable into common stock but constrained by a 9.99% “Maximum Percentage” clause. This means warrant exercises cannot increase Deep Track’s beneficial ownership above 9.99%, so actual future ownership levels will depend on share count changes and any warrant exercises within that cap.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

ProMIS Neurosciences Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

74346M505

(CUSIP Number)

01/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74346M505

1

Names of Reporting Persons

Deep Track Capital, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 902,561.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 902,561.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

902,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 74346M505

1

Names of Reporting Persons

Deep Track Biotechnology Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 703,457.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 703,457.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

703,457.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.79 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

CUSIP No. 74346M505

1

Names of Reporting Persons

David Kroin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 902,561.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 902,561.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

902,561.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 74346M505

1

Names of Reporting Persons

Deep Track Special Opportunities Fund, LP.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 199,104.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 199,104.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

199,104.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.20 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ProMIS Neurosciences Inc.
(b)	Address of issuer's principal executive offices: Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada, M4S 3E2
Item 2.
(a)	Name of person filing: (i) Deep Track Capital, LP (ii) Deep Track Biotechnology Master Fund, Ltd. (iii) David Kroin (iv) Deep Track Special Opportunities Fund, LP.
(b)	Address or principal business office or, if none, residence: (i) 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (ii) c/o Walkers Corporate Limited, 190 Elgin Ave, George Town, KY1-9001, Cayman Islands (iii) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830 (iv) c/o Deep Track Capital, LP, 200 Greenwich Ave, 3rd Floor, Greenwich, CT 06830
(c)	Citizenship: (i) Delaware (ii) Cayman Islands (iii) United States (iv) Delaware
(d)	Title of class of securities: Common Shares, no par value per share
(e)	CUSIP No.: 74346M505
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 902,561
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 902,561
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 902,561
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Deep Track Capital, LP is the relevant entity for which David Kroin may be considered a control person.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deep Track Capital, LP

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:	02/06/2026

Deep Track Biotechnology Master Fund, Ltd.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Director
Date:	02/06/2026

David Kroin

Signature:	/s/ David Kroin
Name/Title:	David Kroin
Date:	02/06/2026

Deep Track Special Opportunities Fund, LP.

Signature:	/s/ David Kroin
Name/Title:	David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP
Date:	02/06/2026

Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of February 6, 2026, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person. The amount beneficially owned by each Reporting Person is determined using 9,034,646 shares, calculated using 2,152,444 Common Stock outstanding as of November 12, 2025 (adjusted for 1 for 25 stock split), according to the 10-Q filed with the SEC on November 12, 2025 and 6,815,296 Common Stock issued according to the issuer's 8-K filed with the SEC on January 30, 2026 and 66,906 Common Stock that would be converted to Common Stock by the Reporting Person up to the Maximum Percentage. The beneficially owned shares include 835,655 Warrants exercisable to common stock, subject to a 9.99% Maximum Percentage exercise limitation. The Issuer shall not effect the exercise of any portion of the Warrants, to the extent that after giving effect to such exercise, the holder collectively would beneficially own in excess of 9.99% (the "Maximum Percentage") of the number of Common Stock outstanding immediately after giving effect to such exercise. Deep Track Capital LP and David Kroin may be deemed to be considered beneficial owners of a combined 835,655 common stock and 835,655 warrants subject to the Maximum Percentage exercise limitation. Deep Track Biotechnology Master Fund Ltd is the beneficial owner of a combined 651,310 common shares and 651,310 warrants subject to the Maximum Percentage exercise limitation. Deep Track Special Opportunities Fund LP is the beneficial owner of 184,345 common shares and 184,345 warrants subject to the Maximum Percentage exercise limitation. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 6, 2026 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin Deep Track Special Opportunities Fund, LP. By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser of Deep Track Special Opportunities Fund, LP

FAQ

What stake does Deep Track Capital report in ProMIS Neurosciences (PMN)?

Deep Track Capital and related entities report beneficial ownership of 902,561 ProMIS common shares, equal to 9.99% of the outstanding common stock as of February 6, 2026. This makes Deep Track a significant institutional holder under SEC reporting rules.

How was the 9.99% ownership in ProMIS Neurosciences (PMN) calculated?

The 9.99% figure is based on 9,034,646 common shares, combining 2,152,444 shares outstanding on November 12, 2025, 6,815,296 shares issued on January 30, 2026, and 66,906 shares potentially convertible within the maximum ownership limit described in the filing.

What warrants does Deep Track hold in ProMIS Neurosciences (PMN)?

Deep Track Capital LP and David Kroin may be deemed beneficial owners of 835,655 warrants exercisable into common shares. These warrants, along with 835,655 common shares, are subject to a 9.99% Maximum Percentage exercise limitation that restricts post-exercise ownership.

How is ownership split among Deep Track entities in ProMIS Neurosciences (PMN)?

Deep Track Biotechnology Master Fund Ltd beneficially owns 651,310 common shares and 651,310 warrants, while Deep Track Special Opportunities Fund LP holds 184,345 common shares and 184,345 warrants. Deep Track Capital LP and David Kroin are deemed beneficial owners of the combined positions.

Does Deep Track aim to influence control of ProMIS Neurosciences (PMN)?

The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of ProMIS. They are also not held in connection with any control-related transaction, other than activities tied to a nomination under Rule 240.14a-11.

What is the 9.99% Maximum Percentage mentioned in the ProMIS (PMN) filing?

The filing describes a 9.99% Maximum Percentage limit on warrant exercises. The issuer will not effect any warrant exercise that would cause the holder collectively to beneficially own more than 9.99% of ProMIS common shares immediately after such exercise.